AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31195337 — intervention group
Group type: COMPARATOR
Intervention: Teriflunomide 7 mg
Number of subjects: 0
Study 27132630 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthwash (n = 30)
Number of subjects: 90
Study 27132630 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cryotherapy (n = 30)
Number of subjects: 90
Study 27132630 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group, n = 30)
Number of subjects: 90
Study 25838191 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-reduction rationale flyer
Number of subjects: 300
Study 25838191 — intervention group
Group type: COMPARATOR
Intervention: No-education control
Number of subjects: 300
Study 25838191 — intervention group
Group type: EXPERIMENTAL
Intervention: Flyer versions 1-4 (different emphasis frames)
Number of subjects: 300
Study 22907764 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified insulin therapy (IIT) - basal-bolus glulisine + glargine administrations
Number of subjects: 46
Study 22907764 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC) - glargine administration + oral antidiabetic drugs
Number of subjects: 46
Study 22907764 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified insulin therapy (IIT)
Number of subjects: 46
Study 22907764 — intervention group
Group type: EXPERIMENTAL
Intervention: rs753482AC+CC (eNOS polymorphism)
Number of subjects: 46
Study 22907764 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline CD34(+)KDR(+) in rs753482AA
Number of subjects: 46
Study 22907764 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest circulating CD34(+)KDR(+) in IIT rs753482AA
Number of subjects: 46
Study 22907764 — intervention group
Group type: COMPARATOR
Intervention: Lowest circulating CD34(+)KDR(+) in SC rs753482AC+CC
Number of subjects: 46
Study 21821303 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib 250mg/day
Number of subjects: 226
Study 21821303 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib 500mg/day
Number of subjects: 226
Study 21821303 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 226
Study 19674382 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm-guided treatment (AGT)
Number of subjects: 210
Study 19674382 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 210
Study 17325332 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin therapy
Number of subjects: 42902
Study 15809789 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Trocar Insertion (DTI)
Number of subjects: 598
Study 15809789 — intervention group
Group type: COMPARATOR
Intervention: Veress Needle (VN)
Number of subjects: 598
Study 11282170 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute MS
Number of subjects: 103
Study 11282170 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable MS
Number of subjects: 103
Study 11282170 — intervention group
Group type: EXPERIMENTAL
Intervention: OIND patients (HIV-1-associated dementia)
Number of subjects: 103
Study 11282170 — intervention group
Group type: EXPERIMENTAL
Intervention: OIND patients (encephalitis)
Number of subjects: 103
Study 11282170 — intervention group
Group type: COMPARATOR
Intervention: 6-methylprednisolone therapy
Number of subjects: 103
Study 11282170 — intervention group
Group type: COMPARATOR
Intervention: IFN-beta1a therapy
Number of subjects: 103
Study 9041233 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-591 100 mg taken twice daily
Number of subjects: 183
Study 9041233 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-591 50 mg taken twice daily
Number of subjects: 183
Study 9041233 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-591 12.5 mg taken twice daily
Number of subjects: 183
Study 9041233 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183
Study 7696378 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg (R,S)‐propranolol.HCl
Number of subjects: 0
Study 7696378 — intervention group
Group type: COMPARATOR
Intervention: 20 mg (S)‐propranolol.HCl
Number of subjects: 0
Study 7696378 — intervention group
Group type: EXPERIMENTAL
Intervention: (S)‐propranolol (20 mg)
Number of subjects: 0
Study 7696378 — intervention group
Group type: EXPERIMENTAL
Intervention: (R)‐propranolol (40 mg)
Number of subjects: 0
Study 3653122 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (25 mg i.v. single dose)
Number of subjects: 20
Study 3653122 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31797417 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 160
Study 31797417 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of aerobic and resistance exercise
Number of subjects: 160
Study 31797417 — intervention group
Group type: COMPARATOR
Intervention: Aerobic exercise
Number of subjects: 160
Study 28274169 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) 10 mg/kg once a day for the first three days of life plus moderate hypothermia
Number of subjects: 44
Study 28274169 — intervention group
Group type: COMPARATOR
Intervention: Hypothermia alone
Number of subjects: 44
Study 29027817 — intervention group
Group type: EXPERIMENTAL
Intervention: 600,000 IU of vitamin D3 (Cholecalciferol) over 10 days in a dose of 60,000 IU/day
Number of subjects: 0
Study 29027817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26327495 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% commercial pomegranate juice
Number of subjects: 64
Study 26327495 — intervention group
Group type: COMPARATOR
Intervention: apple juice (control)
Number of subjects: 64
Study 23690366 — intervention group
Group type: EXPERIMENTAL
Intervention: Annexin A5 anticoagulant activity
Number of subjects: 183
Study 23690366 — intervention group
Group type: COMPARATOR
Intervention: Pediatric controls
Number of subjects: 183
Study 23690366 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with SLE and positive anti-DI antibodies
Number of subjects: 183
Study 23690366 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-DI antibodies
Number of subjects: 183
Study 23690366 — intervention group
Group type: EXPERIMENTAL
Intervention: Lupus anticoagulant (LA)
Number of subjects: 183
Study 20723551 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep restriction (4h time in bed per night for 5 nights)
Number of subjects: 74
Study 20723551 — intervention group
Group type: COMPARATOR
Intervention: Control group (10h time in bed per night throughout the study)
Number of subjects: 74
Study 18755067 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross arch fulcrum
Number of subjects: 32
Study 18755067 — intervention group
Group type: COMPARATOR
Intervention: Opposite fulcrum
Number of subjects: 32
Study 18755067 — intervention group
Group type: COMPARATOR
Intervention: Standard intraoral fulcrum
Number of subjects: 32
Study 18755067 — intervention group
Group type: COMPARATOR
Intervention: Basic extraoral fulcrum
Number of subjects: 32
Study 18755067 — intervention group
Group type: COMPARATOR
Intervention: Finger on finger fulcrum
Number of subjects: 32
Study 18755067 — intervention group
Group type: COMPARATOR
Intervention: Opposite arch fulcrum
Number of subjects: 32
Study 15930485 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.52 g/day DHA from capsules containing DHA-rich algal triglycerides
Number of subjects: 57
Study 15930485 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (control)
Number of subjects: 57
Study 14521638 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline education and individual feedback
Number of subjects: 120
Study 14521638 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 120
Study 11077720 — intervention group
Group type: EXPERIMENTAL
Intervention: Preconceptional education and good metabolic control (group A)
Number of subjects: 61
Study 11077720 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (group B)
Number of subjects: 61
Study 8853760 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (200 micrograms b.d.)
Number of subjects: 10
Study 8853760 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 1635487 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal care provided by registered midwives
Number of subjects: 89
Study 1635487 — intervention group
Group type: COMPARATOR
Intervention: Antenatal care provided by obstetricians
Number of subjects: 89
Study 6367578 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol and colestipol combination
Number of subjects: 47
Study 6367578 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol alone
Number of subjects: 47
Study 6367578 — intervention group
Group type: COMPARATOR
Intervention: Colestipol alone
Number of subjects: 47
Study 6367578 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol alone or in combination
Number of subjects: 47
Study 31484551 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasch model of continuous variables with standardized residual analyses
Number of subjects: 194
Study 31484551 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasch model of continuous variables
Number of subjects: 194
Study 31484551 — intervention group
Group type: EXPERIMENTAL
Intervention: Online dashboard for monitoring possible deductions
Number of subjects: 194
Study 29432383 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01E vaccination at ≤7 days, 10 and 14 weeks
Number of subjects: 480
Study 29432383 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01E vaccination at 10, 14 and 26 weeks
Number of subjects: 480
Study 29432383 — intervention group
Group type: COMPARATOR
Intervention: RTS,S/AS01E vaccination
Number of subjects: 480
Study 29432383 — intervention group
Group type: COMPARATOR
Intervention: Control group (without RTS,S/AS01E)
Number of subjects: 480
Study 26512928 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot gait training (five sessions a week for 5 weeks)
Number of subjects: 28
Study 26512928 — intervention group
Group type: COMPARATOR
Intervention: Usual gait training (control group)
Number of subjects: 28
Study 24029016 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0‐s stimulus response (R[S])
Number of subjects: 0
Study 24029016 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5‐s stimulus response (R[L])
Number of subjects: 0
Study 22551482 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve block (0.375% ropivacaine 6ml/h for 48h)
Number of subjects: 104
Study 22551482 — intervention group
Group type: COMPARATOR
Intervention: Single dose femoral nerve block (30mL of 0.5% ropivacaine)
Number of subjects: 104
Study 20660678 — intervention group
Group type: EXPERIMENTAL
Intervention: DRV/r 600/100 mg BID
Number of subjects: 27
Study 20660678 — intervention group
Group type: EXPERIMENTAL
Intervention: RFB 300 mg QD
Number of subjects: 27
Study 20660678 — intervention group
Group type: EXPERIMENTAL
Intervention: DRV/r 600/100 mg BID plus RFB 150 mg QOD
Number of subjects: 27
Study 20660678 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (DRV/r + RFB)
Number of subjects: 27
Study 17950789 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (PCI) at an off-site center
Number of subjects: 439
Study 17950789 — intervention group
Group type: COMPARATOR
Intervention: Primary percutaneous coronary intervention (PCI) at a tertiary center with cardiac surgery
Number of subjects: 439
Study 16173217 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-electrolyte (CHO-E) fluid replacement
Number of subjects: 0
Study 16173217 — intervention group
Group type: COMPARATOR
Intervention: Water (WAT)
Number of subjects: 0
Study 12554113 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluor‐Protector + Cervitec (Test group)
Number of subjects: 102
Study 12554113 — intervention group
Group type: COMPARATOR
Intervention: Placebo varnish (Placebo group)
Number of subjects: 102
Study 12554113 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Test and Placebo)
Number of subjects: 102
Study 10214002 — intervention group
Group type: EXPERIMENTAL
Intervention: Historical control data adjustment procedure
Number of subjects: 0
Study 10214002 — intervention group
Group type: COMPARATOR
Intervention: Group sequential monitoring
Number of subjects: 0
Study 7861627 — intervention group
Group type: EXPERIMENTAL
Intervention: 2W continuous+TIW
Number of subjects: 115
Study 7861627 — intervention group
Group type: EXPERIMENTAL
Intervention: 4W continuous+TIW
Number of subjects: 115
Study 7861627 — intervention group
Group type: EXPERIMENTAL
Intervention: 8W continuous+TIW
Number of subjects: 115
Study 7861627 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon treatment
Number of subjects: 115
Study 2024591 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonionic iopamidol (Isovue‐370)
Number of subjects: 913
Study 2024591 — intervention group
Group type: COMPARATOR
Intervention: Ionic contrast media, meglumine sodium diatrizoate (Renografin‐76)
Number of subjects: 913
Study 7043754 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin 30 mg (increased to 60 mg from week 2)
Number of subjects: 42
Study 7043754 — intervention group
Group type: COMPARATOR
Intervention: Clomipramine 75 mg (increased to 150 mg from week 2)
Number of subjects: 42
Study 29976075 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance care planning intervention (details on dosage and duration not available)
Number of subjects: 200
Study 29730827 — intervention group
Group type: EXPERIMENTAL
Intervention: INSPIRE + PST
Number of subjects: 755
Study 29730827 — intervention group
Group type: EXPERIMENTAL
Intervention: INSPIRE alone
Number of subjects: 755
Study 29730827 — intervention group
Group type: COMPARATOR
Intervention: Control (delayed INSPIRE access)
Number of subjects: 755
Study 26796956 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintendo™ Wii console intervention, balance board exercises, 2 sessions per week for 3 months
Number of subjects: 760
Study 26796956 — intervention group
Group type: COMPARATOR
Intervention: Usual habits (control group)
Number of subjects: 760
Study 25113556 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal ropivacaine
Number of subjects: 120
Study 25113556 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 120
Study 22287671 — intervention group
Group type: EXPERIMENTAL
Intervention: No supplemental vitamin A for 227 d
Number of subjects: 164
Study 22287671 — intervention group
Group type: EXPERIMENTAL
Intervention: No supplemental vitamin A for 112 d followed by 115 d of supplemental vitamin A
Number of subjects: 164
Study 22287671 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental vitamin A for 112 d followed by no supplemental vitamin A for 115 d
Number of subjects: 164
Study 22287671 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental vitamin A for 227 d
Number of subjects: 164
Study 22287671 — intervention group
Group type: COMPARATOR
Intervention: Cattle without supplemental vitamin A
Number of subjects: 164
Study 22287671 — intervention group
Group type: EXPERIMENTAL
Intervention: Cattle with supplemental vitamin A
Number of subjects: 164
Study 18803678 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human TSH (rhTSH)
Number of subjects: 74
Study 18803678 — intervention group
Group type: COMPARATOR
Intervention: Hypothyroidism
Number of subjects: 74
Study 18803678 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (rhTSH and hypothyroidism)
Number of subjects: 74
Study 16636856 — intervention group
Group type: EXPERIMENTAL
Intervention: Training (T)
Number of subjects: 58
Study 16636856 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 58
Study 15218522 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005%/Timolol maleate 0.5%
Number of subjects: 33
Study 15218522 — intervention group
Group type: COMPARATOR
Intervention: Dorzolamide 2%/Timolol maleate 0.5%
Number of subjects: 33
Study 11834238 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% cellulose sulfate gel (2.5 mL and 5.0 mL doses)
Number of subjects: 0
Study 11834238 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% cellulose sulfate gel (2.5 mL)
Number of subjects: 0
Study 11834238 — intervention group
Group type: COMPARATOR
Intervention: Conceptrol (nonoxynol-9)
Number of subjects: 0
Study 11834238 — intervention group
Group type: COMPARATOR
Intervention: K-Y jelly
Number of subjects: 0
Study 11834238 — intervention group
Group type: COMPARATOR
Intervention: All products (6% cellulose sulfate gel, Conceptrol, K-Y jelly)
Number of subjects: 0
Study 9727542 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab
Number of subjects: 483
Study 9727542 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 483
Study 7506854 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride for twelve months
Number of subjects: 895
Study 7506854 — intervention group
Group type: COMPARATOR
Intervention: PSA values alone with a cutoff of 10 ng/mL at baseline and 5 ng/mL after twelve months of treatment
Number of subjects: 895
Study 2735734 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 30 mg/day
Number of subjects: 20
Study 2735734 — intervention group
Group type: COMPARATOR
Intervention: Reference group (no treatment)
Number of subjects: 20
Study 1167048 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical methenamine gel stick
Number of subjects: 26
Study 1167048 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 31726894 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratumoral injection of DNX-2401 without tumor resection
Number of subjects: 0
Study 31726894 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratumoral injection of DNX-2401 followed by surgical resection 14 days later with a second injection into the resection cavity
Number of subjects: 0
Study 31726894 — intervention group
Group type: EXPERIMENTAL
Intervention: DNX-2401 treatment
Number of subjects: 0
Study 28862375 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular revascularization
Number of subjects: 358
Study 26308291 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro‐En (21 g of leucine‐enriched whey protein with carbohydrate (9 g) and fat (3 g))
Number of subjects: 45
Study 26308291 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro (21 g of leucine‐enriched whey protein without carbohydrate and fat)
Number of subjects: 45
Study 26308291 — intervention group
Group type: COMPARATOR
Intervention: En (isocaloric mixture containing carbohydrate and fat only)
Number of subjects: 45
Study 26308291 — intervention group
Group type: COMPARATOR
Intervention: Pro‐En vs Pro
Number of subjects: 45
Study 26308291 — intervention group
Group type: COMPARATOR
Intervention: Pro‐En vs En
Number of subjects: 45
Study 22153730 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 226
Study 22153730 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 226
Study 22153730 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 226
Study 22153730 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 226
Study 22153730 — intervention group
Group type: COMPARATOR
Intervention: Control group (Olanzapine)
Number of subjects: 226
Study 21459430 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent
Number of subjects: 1140
Study 21459430 — intervention group
Group type: COMPARATOR
Intervention: Everolimus-eluting stent
Number of subjects: 1140
Study 18697183 — intervention group
Group type: EXPERIMENTAL
Intervention: Herba Epimedii water extract
Number of subjects: 90
Study 18697183 — intervention group
Group type: COMPARATOR
Intervention: Water placebo
Number of subjects: 90
Study 16595786 — intervention group
Group type: EXPERIMENTAL
Intervention: Home care nurse-directed treatment strategy
Number of subjects: 0
Study 16595786 — intervention group
Group type: COMPARATOR
Intervention: Primary care physician-directed treatment
Number of subjects: 0
Study 16595786 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 12411756 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline for 24 h (1 ml/kg/h) beginning 12 h prior to catheterization
Number of subjects: 53
Study 12411756 — intervention group
Group type: COMPARATOR
Intervention: Unrestricted oral fluids
Number of subjects: 53
Study 11236819 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive intervention (training in face‐name associations, spaced retrieval, and cognitive stimulation)
Number of subjects: 37
Study 11236819 — intervention group
Group type: COMPARATOR
Intervention: Mock (placebo) intervention
Number of subjects: 37
Study 9709277 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammography screening
Number of subjects: 48569
Study 9709277 — intervention group
Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 48569
Study 8474062 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 10 mg im on Day 0, no corticosteroid (Group 1)
Number of subjects: 33
Study 8474062 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX) 10 mg im on Day 0, prednisolone 15 mg/day per os from D-3 (Group 2)
Number of subjects: 33
Study 8474062 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 10 mg im on Day 0, long-term prednisolone treatment 15 mg/day (Group 3)
Number of subjects: 33
Study 3761104 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (0.3 mg/kg/dose)
Number of subjects: 42
Study 3761104 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (0.1 mg/kg/dose)
Number of subjects: 42
Study 3761104 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (0.2 mg/kg/dose)
Number of subjects: 42
Study 30055883 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU + TCT
Number of subjects: 46
Study 30055883 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 46
Study 29200181 — intervention group
Group type: EXPERIMENTAL
Intervention: PROMIS pain interference scales (4 fixed-length scales including the 6-item Pain Short Form and the 4-, 6-, and 8-item pain interference scales)
Number of subjects: 759
Study 23925581 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex decongestive physical therapy (CDT) including skin care, manual lymphatic drainage, compression bandages, compression garments, and exercises, n = 15
Number of subjects: 31
Study 23925581 — intervention group
Group type: COMPARATOR
Intervention: Complex decongestive physical therapy (CDT) combined with an intermittent pneumatic compression pump, n = 16
Number of subjects: 31
Study 23780502 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg film-coated tablets
Number of subjects: 76